Piramal Pharma cuts exposure to Chinese raw materials to reduce supply risk
Piramal Finance moved higher.
· BS Companies
Piramal is among global drugmakers increasingly seeking to reduce their reliance on China for pharmaceutical ingredients and manufacturing, amid rising geopolitical…
The analysis
Against that, the stock is +3.5% on the day at ₹2,040.00, and has returned -7.2% over three months. It sits 12% below its 52-week high. The financial services sector has moved -9.0% over the same period, so Piramal Finance is running 1.8 points ahead of its peers.
With Piramal Finance, Piramal Pharma and Reliance Industries all implicated, this reads as a Financial Services-level move rather than a company-specific one, which is the more durable kind of signal.
Market context
- It touches several names at once (PIRAMALFIN, PPLPHARMA, RELIANCE), which points to a sector-level rather than company-specific driver.
- Sector exposure: Financial Services, Pharma & Healthcare, Oil & Energy.
In this story
Related coverage
Vodafone Idea zooms 12% after FPO sees 6x subscription; focus shifts to allotment, listing
Jio Platforms may draw more than $20 billion in bids for IPO
Elon Musk vs Mukesh Ambani: Why is Tesla, SpaceX CEO attacking Reliance Industries ahead of Jio Platforms IPO launch?
Why did Japanese chain 7-Eleven shut 31 stores in India despite its ‘long-term’ ambitions?
Jio IPO may trigger Reliance’s next big re-rating. Why Religare sees 47% upside